176 related articles for article (PubMed ID: 32590461)
1. Successful treatment of cutaneous mucormycosis disseminated from pulmonary mucormycosis with liposomal amphotericin B and posaconazole.
Ding XL; Li HM; Du J
Chin Med J (Engl); 2020 Jul; 133(14):1747-1748. PubMed ID: 32590461
[No Abstract] [Full Text] [Related]
2. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.
Rickerts V; Atta J; Herrmann S; Jacobi V; Lambrecht E; Bialek R; Just-Nübling G
Mycoses; 2006; 49 Suppl 1():27-30. PubMed ID: 16961579
[TBL] [Abstract][Full Text] [Related]
3. Disseminated Mucormycosis With Cerebral Involvement Owing to Rhizopus Microsporus in a Kidney Recipient Treated With Combined Liposomal Amphotericin B and Posaconazole Therapy.
Ville S; Talarmin JP; Gaultier-Lintia A; Bouquié R; Sagan C; Le Pape P; Giral M; Morio F
Exp Clin Transplant; 2016 Feb; 14(1):96-9. PubMed ID: 25275881
[TBL] [Abstract][Full Text] [Related]
4. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
5. [Mucormycosis: therapeutic news].
Pilmis B; Lanternier F; Lortholary O
Med Sci (Paris); 2013 Mar; 29 Spec No 1():25-30. PubMed ID: 23510522
[TBL] [Abstract][Full Text] [Related]
6. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.
Cornu M; Bruno B; Loridant S; Navarin P; François N; Lanternier F; Amzallag-Bellenger E; Dubos F; Mazingue F; Sendid B
BMC Pharmacol Toxicol; 2018 Dec; 19(1):81. PubMed ID: 30522521
[TBL] [Abstract][Full Text] [Related]
7. Experimental murine model of disseminated infection by Saksenaea vasiformis: successful treatment with posaconazole.
Salas V; Pastor FJ; Calvo E; Sutton D; García-Hermoso D; Mayayo E; Dromer F; Fothergill A; Alvarez E; Guarro J
Med Mycol; 2012 Oct; 50(7):710-5. PubMed ID: 22458251
[TBL] [Abstract][Full Text] [Related]
8. Rhizopus Infection in a Preterm Infant: A Novel Use of Posaconazole.
Fatemizadeh R; Rodman E; Demmler-Harrison GJ; Dinu D
Pediatr Infect Dis J; 2020 Apr; 39(4):310-312. PubMed ID: 32084112
[TBL] [Abstract][Full Text] [Related]
9. Successful Nonsurgical Eradication of Invasive Gastric Mucormycosis.
El Hachem G; Chamseddine N; Saidy G; Choueiry C; Afif C
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S145-8. PubMed ID: 27521312
[No Abstract] [Full Text] [Related]
10. Cutaneous mucormycosis.
Vulsteke JB; Deeren D
Transpl Infect Dis; 2019 Apr; 21(2):e13039. PubMed ID: 30548761
[TBL] [Abstract][Full Text] [Related]
11. Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.
Goldani LZ; Sugar AM
J Antimicrob Chemother; 1994 Feb; 33(2):369-72. PubMed ID: 8182030
[No Abstract] [Full Text] [Related]
12. Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B.
Erbey F; Kocabaş E; Bayram İ; Soyupak S; Gümürdülü D; Tanyeli A
Tuberk Toraks; 2012; 60(4):375-9. PubMed ID: 23289469
[TBL] [Abstract][Full Text] [Related]
13. Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.
Mezhir JJ; Mullane KM; Zarling J; Satoskar R; Pai RK; Roggin KK
Surg Infect (Larchmt); 2009 Oct; 10(5):447-51. PubMed ID: 19485785
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.
Luo G; Gebremariam T; Lee H; French SW; Wiederhold NP; Patterson TF; Filler SG; Ibrahim AS
Antimicrob Agents Chemother; 2013 Jul; 57(7):3340-7. PubMed ID: 23650163
[TBL] [Abstract][Full Text] [Related]
15. Part 2: mucormycosis: focus on therapy.
Lynch JP; Zhanel GG
Expert Rev Anti Infect Ther; 2023; 21(7):737-748. PubMed ID: 37300820
[TBL] [Abstract][Full Text] [Related]
16. [Amphotericin and posaconazole for gastrointestinal mucormycosis].
Sanduende Otero Y; Moreno López E; Rodríguez Losada M; Roibal MA
Rev Esp Anestesiol Reanim; 2009 Feb; 56(2):131-2. PubMed ID: 19334671
[No Abstract] [Full Text] [Related]
17. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
Bagshaw E; Kuessner D; Posthumus J; Escrig C; Blackney M; Heimann SM; Cornely OA
Future Microbiol; 2017 May; 12():515-525. PubMed ID: 28191796
[TBL] [Abstract][Full Text] [Related]
18. Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B.
Sedlacek M; Cotter JG; Suriawinata AA; Kaneko TM; Zuckerman RA; Parsonnet J; Block CA
Am J Kidney Dis; 2008 Feb; 51(2):302-6. PubMed ID: 18215708
[TBL] [Abstract][Full Text] [Related]
19. Re: 'Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis' by Manesh et al.
Muthu V; Agarwal R; Chakrabarti A
Clin Microbiol Infect; 2023 Nov; 29(11):1461-1462. PubMed ID: 37473841
[No Abstract] [Full Text] [Related]
20. Cutaneous mucormycosis.
Chang H; Wang PN; Huang Y
Infection; 2018 Dec; 46(6):901-902. PubMed ID: 30091018
[No Abstract] [Full Text] [Related]
[Next] [New Search]
